Evidence map›Paper›PMID 32567819›Full record

ArticleACR open rheumatology2020

Expanded Autoantibody Profiles for Subsetting of Native American, African American, and European American Patients With Systemic Lupus Erythematosus.

Carla J Guthridge, Timothy Gross, Magdalene Quintero, Joseph M Kheir, Jeremy Levin, Rebecka L Bourn, Sohail Khan, Michael Peercy, Bobby Saunkeah, Joel M Guthridge and 1 more

Open access · goldAbstract read
In one paragraph

Article in ACR open rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Carla J GuthridgeOklahoma Medical Research Foundation, Oklahoma City.
Timothy GrossOklahoma Medical Research Foundation, Oklahoma City.
Magdalene QuinteroOklahoma Medical Research Foundation, Oklahoma City.
Joseph M KheirOklahoma Medical Research Foundation, Oklahoma City.
Jeremy LevinOklahoma Medical Research Foundation, Oklahoma City.
Rebecka L BournOklahoma Medical Research Foundation, Oklahoma City.
Sohail KhanCherokee Nation, Tahlequah, Oklahoma.
Michael PeercyChickasaw Nation, Ada, Oklahoma.
Bobby SaunkeahChickasaw Nation, Ada, Oklahoma.
Joel M GuthridgeOklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City.
Judith A JamesOklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City.ORCID https://orcid.org/0000-0002-9574-7355
Oklahoma Medical Research Foundation · USCherokee Nation · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Robert Hal Scofield · 2013 to 2026
$68.2M
Oklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2018 to 2026
$8.5M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
RAD-X UP NARCH Supplement: A Cherokee Nation Community-Driven Program for Testing and Contact Tracing (Cherokee PROTECT)S06GM127983 · NIGMS · CHEROKEE NATION · PI KHAN, SOHAIL IMRAN · 2018 to 2022
$6.4M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail SuccessUM1AI144292 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2019 to 2026
$3.3M
National Institute of Allergy and Infectious Diseases U19AI082714National Institute of Allergy and Infectious Diseases UM1AI144292NIAID NIH HHS U19 AI082714NIAID NIH HHS UM1 AI144292NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P30AR053483NIAMS NIH HHS P30 AR073750NIAMS NIH HHS P30AR073750NIGMS NIH HHS S06 GM127983NIGMS NIH HHS S06GM127983NIGMS NIH HHS U54 GM104938NIGMS NIH HHS U54GM104938
6 · The paper itself

Abstract

objectiveMany Native American (NA) patients with systemic lupus erythematosus (SLE) do not exhibit the classical SLE autoantibody profiles of European American (EA) and African American (AA) patients with SLE. The poorer SLE disease outcomes noted in NA patients highlights a need for more equitable diagnostic and prognostic tools for NA patients with SLE. The objective was to identify informative autoantibody profiles for NA, AA, and EA patients with SLE using an expanded set of autoantigens.

methodsSera from 49 NA, 49 AA, and 49 EA age-, sex-, and antinuclear autoantibody titer-matched patients with SLE who met the American College of Rheumatology classification criteria and 10 ethnicity-, sex-, and age-matched controls were tested for autoantibody reactivity by autoantigen microarrays. Autoantibodies that were significantly elevated in patients with SLE compared with ethnicity-specific controls were selected for hierarchical clustering. Differences in clinical criteria between patient clusters were determined by Fisher's exact test and corrected for multiple comparisons.

resultsNA, AA, and EA patients with SLE each had a cluster distinguished by higher levels of anti-Ro52 and another cluster distinguished by nucleic acid-specific autoantibodies. Additional clusters were distinguished in NA patients by elevated extracellular matrix autoantibodies and were distinguished in AA patients by elevated Sm/RNP autoantibody and elevated nucleolin/histone autoantibody. Two EA patient clusters with similar nucleic acid- and Ro52-specific autoantibodies were distinguished by either high or low histone 2A reactivity. Renal manifestations trended higher in the NA Ro52 cluster and were significantly enriched in the AA nucleolin/histone cluster. The AA nucleolin/histone cluster and EA H2A cluster had higher disease activity.

conclusionExpanded autoantibody profiles can identify informative subsets of patients with SLE.

Identifiers

PMID32567819
PMCPMC7368137
OpenAlexW3035925950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.